Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ginwa Enterprise GroupSHSE:600080 +1.26%48 5-Year Yield-on-Cost % is 0.62 as of Jul. 29, 2026, which is 22% above its 10-year median of 0.51. GuruFocus rates SHSE:600080 with a GF Score™ of 48/100 and a GF Value™ of ¥7.53 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 514 Drug Manufacturers companies, Ginwa Enterprise Group ranks worse than 79.18% on this metric.
Ginwa Enterprise Group's yield on cost for the quarter that ended in Mar. 2026 was 0.62.
The historical rank and industry rank for Ginwa Enterprise Group's 5-Year Yield-on-Cost % or its related term are showing as below:
SHSE:600080'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.24 Med: 0.51 Max: 1.81
Current: 0.62
During the past 13 years, Ginwa Enterprise Group's highest Yield on Cost was 1.81. The lowest was 0.24. And the median was 0.51.
SHSE:600080's 5-Year Yield-on-Cost % is ranked worse than 79.18% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.305
vs SHSE:600080: 0.62
Ginwa Enterprise Group (SHSE:600080) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Ginwa Enterprise Group 5-Year Yield-on-Cost % Related Terms
SHSE:600080 vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ginwa Enterprise Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginwa Enterprise Group 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ginwa Enterprise Group's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Ginwa Enterprise Group's 5-Year Yield-on-Cost % falls into.
Ginwa Enterprise Group 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Ginwa Enterprise Group (SHSE:600080) has a 5-Year Yield-on-Cost % of 0.62 as of Jul. 29, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ginwa Enterprise Group and its competitors. This is 22% above median its historical median of 0.51. Over the past decade, Ginwa Enterprise Group's 5-Year Yield-on-Cost % has ranged from 0.24 to 1.81. According to the industry distribution chart, Ginwa Enterprise Group ranks #407 out of 514 companies in the Drug Manufacturers industry, placing it in the top 79.2%.
Is Ginwa Enterprise Group's 5-Year Yield-on-Cost % too high?
Ginwa Enterprise Group's current 5-Year Yield-on-Cost % of 0.62 is 22% above median its 10-year median of 0.51. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 1.81. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.31. Ginwa Enterprise Group's value of 0.62 is 73.1% below this industry median. Based on the distribution chart, Ginwa Enterprise Group ranks #407 out of 514 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ginwa Enterprise Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ginwa Enterprise Group's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ginwa Enterprise Group ranks #407 out of 514 companies for 5-Year Yield-on-Cost %. This places Ginwa Enterprise Group in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.31. Ginwa Enterprise Group's value of 0.62 is 73.1% below this benchmark. Historically, Ginwa Enterprise Group's own 5-Year Yield-on-Cost % has ranged from 0.24 to 1.81 over the past decade. While the company's 10-year median is 0.51 vs. the industry median of 2.31, Ginwa Enterprise Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.31, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginwa Enterprise Group's current 5-Year Yield-on-Cost % of 0.62 is 73.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ginwa Enterprise Group and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginwa Enterprise Group's current 5-Year Yield-on-Cost % is 0.62, which is 22% above median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginwa Enterprise Group stock overvalued right now?
Based on GuruFocus' analysis, Ginwa Enterprise Group (SHSE:600080) is currently considered Possible Value Trap. The stock's GF Value™ is ¥7.53, compared to a current price of ¥4.82 — trading 36% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.62, which is 22% above median its 10-year median of 0.51 and 73.1% below the Drug Manufacturers industry median of 2.31. Ginwa Enterprise Group's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Ginwa Enterprise Group (SHSE:600080), the current 5-Year Yield-on-Cost % is 0.62 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginwa Enterprise Group (SHSE:600080) Overvalued in 2026?
Based on GuruFocus' analysis, Ginwa Enterprise Group stock appears to be undervalued.
The current stock price of ¥4.82 is trading 36% below its estimated GF Value™ of ¥7.53.
GuruFocus considers Ginwa Enterprise Group to be Possible Value Trap.
Key valuation signals for SHSE:600080:
5-Year Yield-on-Cost %: 0.62 (22% above median its 10-year median of 0.51)
GF Value™: ¥7.53 vs. price of ¥4.82 (36% below fair value)
Industry Position: 73.1% below the Drug Manufacturers median (#407 of 514)
No single metric tells the full story. See the SHSE:600080 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginwa Enterprise Group Inc operates in the pharmaceutical industry. The main business is the research and development, production, and sales of drugs, and the product line covers chemical drugs, Chinese patent medicines, raw materials, and health products. The dosage forms include tablets, capsules, granules, powders, mixtures, oral solutions, syrups, external solutions, and more than 100 varieties and specifications.
48GF Score
Get the complete analysis for SHSE:600080
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600080 has been successfully added to your 
